presentation to investors - mitsubishichem-hd.co.jp · pdf filepresentation to investors. ......
Click here to load reader
Post on 21-Aug-2018
Embed Size (px)
March 11, 2015
Yoshimitsu KobayashiPresident & Chief Executive Officer
Mitsubishi Chemical Holdings Corporation
Step 2 (FY2013 - FY2015)
Presentation to Investors
The forward-looking statements are based largely on information availableas of the date hereof, and are subject to risks and uncertainties which may be beyond Company control. Actual results could differ largely, due to numerous factors, including but not limited to the following: Group companies execute businesses in many different fields, such as information and electronics, performance products, polymers and processed products, pharmaceuticals, carbon and inorganic products, and petrochemicals, and these business results are subjected to influences of world demands, exchange rates, price and procurement volume of crude oil and naphtha, trends in market prices, speed in technology innovation, National Health Insurance price revision, product liabilities, lawsuits, laws, and regulations.
List of Abbreviations
MCHC: Mitsubishi Chemical Holdings CorporationMCC: Mitsubishi Chemical CorporationMTPC: Mitsubishi Tanabe Pharma CorporationMPI: Mitsubishi Plastics, Inc.MRC: Mitsubishi Rayon Co., Ltd.LSII: Life Science Institute, Inc.TNSC: Taiyo Nippon Sanso Corporation
APIC: API CorporationBARDA: Biomedical Advanced Research
and Development AuthorityCRK: Chuo Rika Kogyo CorporationHLC: Healthy Life Compass CorporationLSIM: LSI Medience CorporationNEDO: New Energy and Industrial Technology
Development OrganizationNIMS: National Institute for Materials ScienceNSCI: The Nippon Synthetic Chemical Industry Co., Ltd.QKK: Qualicaps Co., Ltd.
ALS: Amyotrophic lateral sclerosisBPA: Bisphenol-ACAE: Computer aided engineeringCD: Crohn's diseaseCIDP: Chronic inflammatory demyelinating
polyradicaloneuropathy DPC: Diphenyl carbonateEO: Ethylene oxideEV: Electric vehicleEVOH: Ethylene vinyl alcoholFPD: Flat panel displayGaN: Gallium nitrideHEV: Electric vehicleHib: Haemophilus influenza type bICT: Information and communication technologyLiB: Lithium-ion batteryMMA: Methyl methacrylateMOCVD: Metal organic chemical vapor depositionMOS: Management of SustainabilityMOT: Management of TechnologyMS: Multiple sclerosis OLED: Organic light emitting diodeOPV: Organic photovoltaic
FY2011: April 1, 2011 March 31, 2012FY2012: April 1, 2012 March 31, 2013FY2013: April 1, 2013 March 31, 2014FY2014: April 1, 2014 March 31, 2015FY2015: April 1, 2015 March 31, 2016
Note: Product names, brand names, service names, and technology names used in this presentation material are denoted in italics and are trademarks or registered trademarks of the MCHC Group in Japan and/or overseas. Other product names, brand names, and service names may also be protected.
PC: PolycarbonatePE: PolyethylenePCM: Prepreg compression moldingPHEV: Plug-in hybrid electric vehiclePHL: PhenolPMMA: Polymethyl methacrylatePP: PolypropylenePS: PsoriasisPTA: Terephthalic acidPVC: Polyvinyl chloridePVOH: Polyvinyl alcoholRTM: Resin transfer moldingSAP: Super absorbent polymerSBU: Strategic business unitSM: Styrene monomerSMC: Sheet molding compoundUTT: UtilityVLP: Virus-like particlesZEB: Zero energy building
1. Group Overview and Performance Review
2. Progress in Principal Businesses (Comparison with Step 2)
2-1. Performance Products
2-2. Health Care
2-3. Industrial Materials
3. Challenges of Formulating the Next Medium-term Management Plan
*Listed company**Net sales, employees (as of March 31, 2014)
The KAITEKI Institute, Inc.The KAITEKI Institute, Inc.
MCHC* Net sales (consolidated): 3,498.8 billion**Employees (consolidated): 56,031**Oct. 2005
Mitsubishi Chemical Holdings America, Inc.Mitsubishi Chemical Holdings America, Inc.
Mitsubishi Chemical Holdings (Beijing) Co., Ltd.Mitsubishi Chemical Holdings (Beijing) Co., Ltd.
Mitsubishi Chemical Holdings Europe GmbH Mitsubishi Chemical Holdings Europe GmbH
Mitsubishi Chemical Holdings Corporate Staff, Inc.Mitsubishi Chemical Holdings Corporate Staff, Inc.
Business linesPerformance products,Industrial materials, etc.
Business linesPharmaceuticals, etc.
Business linesPlastic products, etc.
Business linesChemical products,
resins, fibers, carbon fiberand composite materials,
membrane bioreactors, etc.
Net sales (consolidated) 412.7 billion**
Net sales (consolidated) 606.2 billion**
Net sales (consolidated)442.7 billion**
MCC MPIOct. 2005 Oct. 2007 Apr. 2008 Apr. 2010
Net sales (consolidated)2,159.7 billion**
Business linesHealthcare and medical ICT, support for pharmaceutical development and advanced
MCHC R&D Synergy Center, Inc.MCHC R&D Synergy Center, Inc. Apr. 2014
Net sales (consolidated)[118.7 billion]**
1-1. Group Overview
Business linesIndustrial gases,
Net sales (consolidated)522.7 billion**
Oct. 2013: Strengthening capital and business alliance (ownership ratio: 27%)Sep. 30, 2014: Commenced TOBNov. 12, 2014: Completed payment Thereafter, TNSC became a consolidated subsidiary (with 50.6% MCHC ownership)
Net sales (consolidated): Approx. 4 trillionOverseas sales ratio: Approx. 40%Employees (consolidated): Approx. 70,000Overseas employees: Approx. 23,000(Figures for fiscal 2014 were calculated as the simple summation of TNSC results with those of the Group.)
Recording mediaInformation and electronics
-related productsImaging supplies
Chemical derivatives Synthetic fiber materials
Diagnostic reagentsand instruments
Performance ProductsElectronics ApplicationsDesigned Materials
Chemical fibersPharmaceutical formulationmaterials
1-2. Business Domains
3,166.8 3,208.2 3,088.6
FY2008 FY2009 FY2010 FY2011 FY2012 FY2013 FY2014
Net salesOperating income
1-3. Financial Results and Fiscal 2014 Outlook
Net sales Operating income( billion)
Consolidated TNSC in 3Q fiscal 2014 through TOB
Forecasting major increase in income in fiscal 2014 (+145% Y-o-Y) because of this and other factors
(Figures announced Nov. 27, 2014)Notes:Includes effects of adopting uniform date for account closings in fiscal 2013: Net sales: 151.9 billion; Operating income: 3.9 billionIncludes effects of consolidating TNSC in fiscal 2014: Net sales: 275.0 billion; Operating income: 17.5 billion
Designed Materials: Conditions firm Health Care: Conditions firm for pharmaceuticals and healthcare solutions Polymers: Outlook for major increase in income in MMA/PMMA
Domains SegmentsFY2013 actual results
FY2014 forecasts* Change
Accumulated through 3Q**
Electronics Applications (5.5) (2.0) +3.5 (2.3)
Consolidation of TNSC (Chemicals)[3Q fiscal 2014]
Outlook for inventory valuation loss* for naphtha and paraxylene in Chemicals and marginal gain* for polyolefin in Polymers[3Q and 4Q fiscal 2014]
Outlook for increase in income in Designed Materials, Health Care, and Polymers
*Overall impact: (Approx. 18.0 billion)
DesignedMaterials 46.5 55.5 +9.0 41.7 75.1%
Health Care Health Care 68.3 70.0 +1.7 70.7 101%
Chemicals 0.7 17.5 +16.8 2.2 12.6%
Polymers 2.3 20.5 +18.2 13.7 66.8%
Others 5.7 6.5 + 0.8 3.3 50.8%
Corporate (7.5) (8.0) (0.5) (5.0)
Total 110.5 160.0 + 49.5 124.3 77.7%
Operating income ( billion)
*Figures announced Nov. 27, 2014**Figures announced Feb. 4, 2015
1-4. Operating Income by Segment:Fiscal 2013 Actual Results vs. Fiscal 2014 Forecasts
Includes effects of adopting uniform date for account closings in fiscal 2013: Net sales: 151.9 billion; Operating income: 3.9 billion)Includes effects of consolidating TNSC in fiscal 2014: Net sales: 275.0 billion; Operating income: 17.5 billion
41.0 (Accumulatedthrough 3Q:
FY2015Step 2 Plan
Increase income by accelerating development of growth fields
Operating income ( billion)
2-1. Performance Products: Progress
Growth fields Lithium-ion battery materials
Organic synthesis (NSCI)
Carbon fiber and composite materials,
*Figure announced Nov. 27, 2014**Figure announced Feb. 4, 2015
2-1-1. Electronics Applications: Principal Businesses